Abstract Our aim was to study, at the same glycemic control, how treatment with either the insulin secretagogue repaglinide or exogenous insulin aspart affects endogenous insulin secretion, plasma insulin and IAPP (islet amyloid polypeptide) levels, GH-IGF (growth hormone-insulin-like growth factor) axis and plasma lipoprotein concentrations in patients with type 2 diabetes. Five patients, age 65.0 ± 4.1 years (mean ± SE), body weight 82.5 ± 5.0 kg, BMI (body mass index) 27.7 ± 1.5 kg/m 2 were treated for 10 weeks with repaglinide or insulin aspart in a randomized, cross-over study. At the end of each treatment a 24-h metabolic profile was performed. Blood glucose, C-peptide, free human insulin, free total (human and analogue) insulin, proinsulin, IAPP, IGF-I, IGFBP-1 (IGF binding protein-1), GHBP (growth hormone binding protein) and plasma lipoprotein concentrations were measured. Similar 24-h blood glucose profiles were obtained with repaglinide and insulin aspart treatment. During the repaglinide treatment, the meal related peaks of C-peptide and free human insulin were about twofold higher than during treatment with insulin aspart. Proinsulin, GHBP were higher and IAPP levels tended to be higher during repaglinide compared to insulin aspart. Postprandial plasma total cholesterol, triglycerides and apolipoprotein B concentrations were higher on repaglinide than on insulin aspart treatment. Our results show that, at the same glycemic control, treatment with exogenous insulin aspart in comparison with the insulin secretagogue repaglinide result in a lower endogenous insulin secretion, and a tendency towards a less atherogenic postprandial lipid profile.
Introduction
Cardiovascular diseases are the leading cause of morbidity and mortality in patients with type 2 diabetes and lipid disturbances are of great importance for development of these complications [1, 2] . Dyslipidemia, associated with type 2 diabetes, is characterized by increased levels of triglycerides (TG), reduced levels of high-density lipoprotein (HDL) cholesterol, while total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol may be either normal or elevated [3] . Postprandial lipemia is a characteristic feature of diabetic dyslipidemia and a risk factor for premature atherosclerosis [4, 5] .
Treatment of type 2 diabetes entail, beside life style changes, oral hypoglycemic agents and when needed exogenous insulin with the goal to maintain glycemic levels as close as possible to the nondiabetic range [6] . Insulin aspart and the insulin secretagogue repaglinide have been developed to have an onset and duration of action that closely matches the postprandial blood glucose peak [7] [8] [9] [10] [11] .
Insulin and the liver have central roles in lipid metabolism [12] . Improving glycemic control by exogenous insulin in patients with type 2 diabetes and insufficient glycemic control on treatment with oral hypoglycemic agent alters the lipoprotein profile towards a less atherogenic pattern [13, 14] . Independent of glycemic control the mode of treatment, insulin secretagogue versus exogenous insulin, may alter the lipoprotein profile possibly by affecting portal insulin delivery to the liver [15] [16] [17] . This can also have importance for the GH-IGF axis [18] , since insulin upregulates the GHR and GHBP level and down regulates the production of IGFBP-1 in the liver [19] [20] [21] [22] .
In patients with type 2 diabetes we compared effects of an insulin secretagogue (repaglinide) and an insulin analogue (aspart) on insulin secretion, lipoprotein profile and GH-IGF axis, at the same glycemic control.
Research design and methods

Patients
Five patients (two men and three women), age 65.0 ± 4.1 years (mean ± SE) (range 52-77 years), body weight 82.5 ± 5.0 kg, BMI 27.7 ± 1.5 kg/m 2 and known diabetes duration for 5.0 ± 1.6 (range 2-9) years took part in this study. Two patients had well-controlled hypertension, while no patients had a history of cardiovascular disease. All patients had normal renal function and no retinopathy. Previous treatment with oral antihyperglycemic agents before the study were metformin only in two patients, sulphonylureas only in one patient and combination treatment of metformin and sulphonylureas in two patients. None of the patients were treated with lipid lowering agents.
Study design
Patients with type 2 diabetes mellitus treated with oral hypoglycemic agents (sulphonylurea and/or metformin) were invited to take part in this open label, randomized, cross-over study. The patients were randomized to start with either insulin aspart (Novorapid Ò U-100, Novo Nordisk, Denmark) or repaglinide (Novonorm Ò , Novo Nordisk, Denmark) and during the study other oral hypoglycemic agents were withdrawn. The treatment was given for a period of 10 weeks and all patients were then switched to the alternative treatment for another 10 weeks. The patients were instructed to monitor blood glucose frequently, before and 1.5-2 h after the main meals and at bedtime, for adjusting therapy. Insulin aspart or repaglinide were administered immediately before the main meals. Adjustment of insulin and repaglinide doses was done in cooperation with the staff of the diabetes unit. Target preprandial plasma glucose concentrations were 4-7 mmol/l and postprandial (1.5-2 h after a main meal) below 10 mmol/l. The protocol allowed addition of intermediate acting NPH insulin given during the evening if acceptable fasting blood glucose control was not achieved. During the last 4 weeks of each treatment period the doses were not changed.
At the end of each 10-week period, a 24-h profile with frequent blood sampling was performed for glucose, Cpeptide, free human insulin and free total insulin. All patients arrived at 16:00 to the clinic. The patients had dinner at 17:00, breakfast at 07:00 and lunch at 12:00. The total caloric intake during the profile days was 1,852 kcal consisting of 52% carbohydrates, 22% proteins, 25% fat and 1% alcohol. Between 17:00-19:00, the blood samples were drawn every 30 min and thereafter every 2 h until 06:50 in the morning. In the morning, the blood samples were taken every 10 min from 06:50 until 08:00, and thereafter, every hour until 16:00. To determine the lipoprotein profile, blood samples were drawn fasting at 06:50 and nonfasting at 11:00 and 15:00. Fasting blood samples were drawn to determine IGF-I and GHBP. Fasting and postprandial blood samples were used to determine proinsulin, IAPP and IGFBP-1 (times are indicated in the figures).
The study was performed according to the recommendations of the Declaration of Helsinki and the local ethical committee approved the protocol. All patients gave their informed consent.
Biochemical analysis
Blood glucose was analyzed by the HemoCue Ò (Hemocue Inc., Mission Viejo, CA, USA). A1c (reference range: 3.2-5.4%) was analyzed with reverse-phase partition chromatography on a cation exchanger using high-performance liquid chromatography (HPLC; Auto A1C HA 8110, Boehringer Mannheim). C-peptide was measured with an enzyme-linked immunosorbent assay (ELISA) from DakoCytomation (DakoCytomation Ltd., Cambridgeshire, UK), based on two monoclonal antibodies against C-peptide. Plasma free insulin was measured after removal of insulin antibodies and antibody-bound insulin by polyethyleneglycol (PEG) precipitation [23] . Free human insulin was measured by Mercodia Insulin ELISA (Mercodia AB, Uppsala, Sweden) using a two-site enzyme immunosorbent assay containing two monoclonal antibodies against human insulin, with no cross-reactivity with insulin aspart [24] . Human insulin was used for the standard curve. Plasma free total insulin was measured by Mercodia Iso-Insulin ELISA (Mercodia AB, Uppsala, Sweden) using a two-site enzyme immunoassay containing two monoclonal antibodies crossreacting equally with human insulin and insulin aspart [24] . The plasma proinsulin was analyzed by an ELISA two-site enzyme immunosorbent assay (Mercodia AB, Uppsala, Sweden). Total serum IGF-I was measured by a one-step enzyme-linked immunosorbent assay (ELISA) after acidethanol-extraction from its binding protein with a commercial kit from Diagnostic System Laboratories (Webster, TX, USA). The assay was performed according to the manufacturer's protocol. Plasma IGFBP-1 was determined by a two-step enzyme-linked immunosorbent assay using a kit from Diagnostic System Laboratories (Webster, TX, USA). Serum human IAPP was measured by a monoclonal antibody-based sandwich immunosorbent assay (Linco Research Inc, USA). The capture antibody recognizes IAPP, IAPP acid (deamidated IAPP), a 1-20 fragment of IAPP, but not reduced IAPP. The detection antibody binds to reduced or unreduced human IAPP but not IAPP acid, and is complexed with streptavidin-alkaline phosphatase.
In brief, determination of lipoproteins and apolipoprotein A-1 and B, were performed as described below. Plasma very low density lipoprotein (VLDL) was separated from low (LDL) and high (HDL) density lipoproteins with preparative ultracentrifugation at d = 1.006. Apolipoprotein B-containing lipoproteins were precipitated in the infranatant using phosphotungstic acid/magnesium chloride leaving HDL in solution. LDL cholesterol concentrations were calculated by subtraction of values of the infranatant after precipitation from the values before precipitation. Cholesterol was determined by Monotest CHOD-PAP and triglycerides GPO-PAP (Boehringer Mannheim). Apolipoproteins A-1 and B were determined by electroimmunoassay [25, 26] . Free fatty acids (FFA) were analyzed according to Ho [27] .
Statistical analysis
Statistical comparisons were made with SPSS program (SPSS Inc. Headquarters, Chicago, IL, USA). The results are presented as means ± SE. Paired-samples t test was used for comparisons and when the values did not have a Gaussian distribution, the Wilcoxon paired-sample test was used. A P value less than 0.05 were considered statistically significant.
Results
Glycemic control, C-peptide, free human insulin, free total insulin, proinsulin and IAPP during repaglinide and insulin aspart treatment After dose titration, all patients on repaglinide treatment received 12 mg daily (4 mg before each main meal), while the daily dose of insulin aspart varied from 13 to 46 U (4-20 U at breakfast, 5-15 U at lunch and 4-15 U at dinner). Due to insufficient glycemic control in the morning, one patient received Insulatard Ò 16 U during repaglinide and 22 U during insulin aspart treatment, at bedtime (22:00). There were no differences in the 24-h blood glucose profiles (Fig. 1a) or the 24-h area under the curve (AUC) 17.1 ± 1.4 during treatment with repaglinide versus 16.0 ± 1.2 insulin aspart (NS). The corresponding glycated hemoglobin A1c values were 6.1 ± 0.4% at the end of repaglinide therapy and 5.9 ± 0.3% at the end of insulin aspart therapy (NS).
C-peptide concentrations were significantly higher during repaglinide treatment compared to insulin aspart treatment (AUC 2,453 ± 502 vs. 1,153 ± 250; P = 0.02) (Fig. 1b) . Calculated during 0-2 h intervals after the main meal, AUC (AUC (0-2 h) ) for C-peptide was higher with repaglinide than with insulin aspart after breakfast (AUC breakfast (0-2 h) 2,909 ± 554 vs. 1,506 ± 371; P = 0.01) and lunch (AUC lunch (0-2 h) 3,025 ± 587 vs. 1,110 ± 296; P = 0.02).
Free human insulin levels ( Fig. 1c) were significantly higher on repaglinide than on insulin aspart therapy (AUC 215 ± 61 vs.128 ± 30; P \ 0.05). AUC for free human insulin calculated during 0-2 h post meal showed higher values after breakfast (AUC breakfast (0-2 h) 397 ± 92 vs. 232 ± 55; P = 0.04) and lunch (AUC lunch (0-2 h) 300 ± 86 vs. 145 ± 35; P = 0.004) during repaglinide than insulin aspart treatment.
AUC of 24-h free total insulin (which measures both endogenous free human insulin and insulin aspart) levels were not significantly different between repaglinide and insulin aspart treatment (Fig. 1d) . Insulin aspart gave higher AUC of free total insulin than repaglinide treatment did (AUC breakfast (0-2 h) 569 ± 90 vs. 344 ± 58; P = 0.04).
Proinsulin levels were higher when measured during repaglinide treatment than during treatment with insulin aspart (Fig. 2a) .
IAPP levels tended to be higher during repaglinide compared to insulin aspart treatment (NS). In comparison with the fasting state, higher IAPP levels were found postprandially during both treatments (P = 0.03) (Fig. 2b) .
IGF-I, IGFBP-1 and GHBP
Fasting plasma IGF-I concentration was 220 ± 19 ng/ml during treatment with insulin aspart and 226 ± 15 ng/ml during treatment with repaglinide (NS). Compared to fasting levels, the IGFBP-1 levels were lower during repaglinide (P \ 0.05), but not during insulin aspart treatment (NS) (Fig. 2c) . Repaglinide treatment increased plasma GHBP concentration compared with insulin aspart (1,094 ± 112 vs. 942 ± 143 pmol/l; P = 0.02).
Lipoprotein concentrations
The mean plasma lipoprotein concentrations were within normal limits when determined at the end of the run-in period. Insulin aspart treatment resulted in lower postprandial levels of total triglycerides at 11:00 (P = 0.001) and at 15:00 (P = 0.03) than repaglinide treatment (Table 1) . Insulin aspart also decreased the postprandial levels of total cholesterol at 11:00 (P = 0.02) when compared with repaglinide treatment (Table 1) . No significant difference was observed in LDL cholesterol or in HDL cholesterol concentration between insulin aspart and repaglinide treatment (Table 1) .
The apolipoprotein B levels were lower during insulin aspart therapy than during repaglinide therapy (P = 0.04) at 15:00 (Table 1 ). There was a tendency towards lower postprandial FFA levels at 11:00 during insulin aspart than during repaglinide treatment (P = 0.06). The ratio between apolipoprotein B and apolipoprotein A-1 (apolipoprotein B/apolipoprotein A-1) was similar during repaglinide and insulin aspart treatment (Table 1) .
During repaglinide treatment, the 4-h postprandial levels of total triglycerides (P = 0.02), total cholesterol (P = 0.04), apolipoprotein A-1 (P = 0.01) and apolipoprotein B (P = 0.005) were higher than in the fasting state. Also during repaglinide treatment, at 8-h from the fasting state, total triglycerides level (P = 0.04) was higher, whereas LDL cholesterol level (P = 0.03) was lower. During insulin aspart, the 8-h postprandial level of apolipoprotein B (P = 0.04) was higher, whereas FFA levels (P = 0.04) were lower when compared to the fasting state (Table 1) .
Discussion
Different approaches can be used to control hyperglycemia in patients with type 2 diabetes [6] . In this study, we compared the effects of two rapid-acting treatments that give pronounced effects on the postprandial metabolism by increasing endogenous insulin secretion or by administration of a rapid-acting exogenous insulin analogue, Fig. 1 24-h profiles of a blood glucose, b plasma C-peptide, c plasma free human insulin and d plasma free total insulin concentration (mean ± SE) in 5 patients with type 2 diabetes treated with insulin aspart (square) and repaglinide (triangle); (* signify P \ 0.05, ** signify P \ 0.01) respectively. We aimed at similar glucose control, to be able to compare these treatment principles without being influenced by differences in glycemia. This goal was achieved as the 24-h blood glucose profiles obtained were similar and there was no significant difference in A1c. While a few studies have been performed comparing effects of insulin treatment with oral hypoglycemic agents during similar glycemic control [15, 16] , this is the first study comparing these rapid-acting treatments with main effects in the postprandial phase. We found differences in a number of variables including lipid metabolism and the IGF-system.
Repaglinide stimulated the secretion of endogenous insulin more than insulin aspart as shown by increased circulating levels of C-peptide, human insulin and proinsulin. These results are in accordance with previous studies showing enhanced insulin secretion after treatment with other insulin secretagogues as sulfonylureas [28, 29] and metiglinides [30, 31] . In this study, we were able to determine the contribution of human insulin and insulin aspart separately by using antibodies able to interact with human insulin, but not cross-reacting with insulin aspart [24] . We found that administration of insulin aspart tended to accentuate total (endogenous ? aspart) insulin peaks and lower basal (overnight) total insulin levels compared with repaglinide therapy. Exogenous insulin administration lowers endogenous insulin secretion, an effect that seems to be due mainly to the reduction of blood glucose concentration and probably not by a negative feed-back on endogenous insulin secretion by insulin itself [1, 13] .
Proinsulin and pro-IAPP are converted by the same endopeptidases to insulin, C-peptide, and IAPP, respectively, and co-secreted by pancreatic b-cells thereafter [32, 33] . In our study, the levels of IAPP increased at breakfast and tended to be higher when the patients were treated with repaglinide compared to insulin aspart in agreement with previous studies of treatment with other insulin secretagogues in comparison with insulin [34, 35] . A growing body of evidence suggests that islet amyloid deposits may play an important role in the loss of b-cells and the progressive decline in insulin secretion characteristic of type 2 diabetes [33] and the degree of amyloid deposition correlates with severity of the disease in humans [36] [37] [38] .
Increased proinsulin levels are associated with increased cardiovascular risk factors in both subjects without [39] and with type 2 diabetes [40] , but it is debatable whether proinsulin is just a marker of compensatory increase of insulin secretion in insulin resistant individuals or if proinsulin has a mechanistic effect by itself in this respect. To see if the changes in endogenous insulin secretion, i.e., portal insulin level affected the IGF-system, we determined IGF-I, IGFBP-1 and GHBP. The significant change in the GHBP level between repaglinide and aspart treatment might reflect an alteration in GH receptors similar to what previously has been shown in type 1 diabetes [21, 22, 41, 42] . There is evidence that insulin down regulates the production of IGFBP-1 [19] [20] [21] [22] . We obtained a tendency to lower IGFBP-1 levels with repaglinide compared to aspart, which might reflect that the higher portal insulin levels during treatment with repaglinide suppress hepatic production of IGFBP-1 [29] . Gibson et al. [29] found that treatment with sulfonylurea depresses both fasting and circadian levels of IGFBP-1 when compared with multiple insulin injections, which support this hypothesis. IGF-I, which has been shown to be low in patients with type 2 diabetes treated with insulin due to secondary failure [43] , showed no difference between the treatments in our study.
When glycemic control is improved in patients with type 2 diabetes concomitant changes of the lipoprotein concentrations are found with marked reductions of triglyceride-rich lipoproteins and also increased HDL cholesterol concentrations [4] . In our study, an aim was to investigate how treatment with a rapid-acting insulin analogue affects the lipoprotein profile in comparison with a short-acting insulin secretagogue with similar glycemic control in order to minimize the influence of glycemia per se. We emphasized measurements of postprandial lipoprotein levels as both treatments have the most pronounced effect in this phase. During insulin treatment, lowering of postprandial triglyceride levels and of apolipoprotein B were found when compared to treatment with repaglinide. While there is no previous study that has compared fasting and postprandial lipemia between insulin aspart and repaglinide, the effect by insulin and sulphonylurea on fasting lipoprotein levels was studied by Romano et al. [15] . They found lower fasting triglycerides and higher HDL 2 cholesterol during insulin therapy than during treatment with glyburide and related these differences to lower production of large VLDL1 particles and a lowered activity of hepatic lipase during insulin treatment [15] . Although VLDL subfractions and hepatic lipase activity were not measured in our study, it seems reasonable that similar changes explain the differences we found in postprandial lipemia between insulin aspart and repaglinide treatment as both repaglinide and sulphonylureas are considered to exclusively act as insulin secretagogues [44] . In a study by Ruotolo et al. [45] , intraperitoneal insulin administration to patients with type 1 diabetes increased hepatic lipase activity, which is in support of this concept. Our results showed a tendency towards lower postprandial FFA levels during insulin aspart than during repaglinide treatment, which suggests a decrease in FFA flux to the liver causing a lower hepatic TG production.
There were no differences in the fasting lipoprotein profile which is coherent with the short action of both therapies used as they were both administered during daytime with the last dose given at dinner. In a previous study [34] , we found lower fasting triglycerides but higher LDL cholesterol concentrations during insulin treatment than during treatment with insulin in combination with glyburide, which is a more long-acting insulin secretagogue than repaglinide [46] . Data on repaglinide effects on the lipid profile are divergent which might possibly be explained by that mostly fasting measurements of lipoprotein concentrations have been performed. One short-term (20 days) study on 25 patients of repaglinide stated that the drug produced statistically significant decreases from baseline in both total cholesterol and triglycerides but did not provide specific data [47] . A larger, long-term study, found no significant changes from baseline in total cholesterol, HDL cholesterol, LDL cholesterol or total triglyceride levels [46] . In a third study, repaglinide significantly increased HDL cholesterol, LDL cholesterol and total cholesterol from baseline, but did not significantly affect triglycerides [48] . In summary, at the same glycemic control, treatment with exogenous insulin aspart in comparison with the insulin secretagogue repaglinide results in a much lower endogenous insulin secretion, and a tendency towards a less atherogenic postprandial lipid profile.
